(Bloomberg)--Bristol-Myers Squibb Co.’s immune cancer therapy won approval from U.S. regulators for a broader population of lung cancer patients, a boost for a drug that’s expected to become a blockbuster.
The decision by the Food and Drug Administration came almost three months ahead of schedule, following a trend of quicker clearances for new cancer drugs by the agency.
In March, Opdivo was approved three months ahead of plan for use in patients with advanced squamous, non-small cell lung cancer whose disease had progressed during or after trying chemotherapy.
The latest approval is for non-squamous, non-small cell lung cancer whose disease has progressed during or after chemotherapy. The non-squamous form of the cancer accounts for about 45 percent to 60 percent of lung cancer cases.
For the average U.S. patient, Opdivo costs about $12,500 a month, or $150,000 for a year of therapy, a Bristol-Myers spokeswoman said.
Opdivo was also approved last week for use in combination with another immune therapy drug in a form of melanoma. That combination will cost $256,000, on average, for a year of treatment.
Opdivo targets a cellular pathway known as PD-1, which restricts the body’s immune system from attacking cancer cells. The drug is expected to expand from $2.15 billion of sales in 2016 to $5.27 billion in 2018, according to analysts’ estimates compiled by Bloomberg.
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
